Compare KVHI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | IPHA |
|---|---|---|
| Founded | 1978 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.0M | 189.5M |
| IPO Year | 1996 | N/A |
| Metric | KVHI | IPHA |
|---|---|---|
| Price | $9.09 | $1.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | ★ 341.2K | 9.5K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $9,622,000.00 | N/A |
| Revenue This Year | $28.90 | $180.36 |
| Revenue Next Year | $31.85 | N/A |
| P/E Ratio | $294.83 | ★ N/A |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $5.09 | $1.18 |
| 52 Week High | $13.00 | $2.63 |
| Indicator | KVHI | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 52.73 |
| Support Level | $8.80 | $1.73 |
| Resistance Level | $9.71 | $1.97 |
| Average True Range (ATR) | 0.72 | 0.09 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 55.84 | 36.80 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.